List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7617904/publications.pdf Version: 2024-02-01



DIFTRO CHEZZI

#	Article	IF	CITATIONS
1	The effect of radiofrequency electromagnetic fields (RF-EMF) on biomarkers of oxidative stress in vivo and in vitro: A protocol for a systematic review. Environment International, 2022, 158, 106932.	10.0	10
2	Special issue "Extracellular Vesicles and Exosomes― Free Radical Biology and Medicine, 2022, 184, 12-13.	2.9	0
3	Mitochondrial ROS, ER Stress, and Nrf2 Crosstalk in the Regulation of Mitochondrial Apoptosis Induced by Arsenite. Antioxidants, 2022, 11, 1034.	5.1	13
4	Online information on medical cannabis is not always aligned with scientific evidence and may raise unrealistic expectations. Journal of Cannabis Research, 2022, 4, .	3.2	6
5	Release of redox enzymes and micro-RNAs in extracellular vesicles, during infection and inflammation. Free Radical Biology and Medicine, 2021, 169, 248-257.	2.9	10
6	Online information on face masks: analysis of websites in Italian and English returned by different search engines. BMJ Open, 2021, 11, e046364.	1.9	1
7	Redox regulation of immunity and the role of small molecular weight thiols. Redox Biology, 2021, 44, 102001.	9.0	8
8	How the redox state regulates immunity. Free Radical Biology and Medicine, 2020, 157, 3-14.	2.9	44
9	Epistemological challenges of the oxidative stress theory of disease and the problem of biomarkers. , 2020, , 13-27.		1
10	Editorial: Translational Insights Into Mechanisms and Therapy of Organ Dysfunction in Sepsis and Trauma. Frontiers in Immunology, 2020, 11, 1987.	4.8	4
11	C-Reactive Protein Predicts Further Ischemic Events in Patients With Transient Ischemic Attack or Lacunar Stroke. Frontiers in Immunology, 2020, 11, 1403.	4.8	13
12	Online Information of Vaccines: Information Quality, Not Only Privacy, Is an Ethical Responsibility of Search Engines. Frontiers in Medicine, 2020, 7, 400.	2.6	13
13	On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological Reviews, 2020, 72, 801-828.	16.0	70
14	Demystifying Oxidative Stress. Handbook of Experimental Pharmacology, 2020, 264, 3-26.	1.8	10
15	Automatic Identification of Information Quality Metrics in Health News Stories. Frontiers in Public Health, 2020, 8, 515347.	2.7	4
16	Editorial: Medicine and Society. Frontiers in Medicine, 2020, 7, 570551.	2.6	0
17	Editorial: Dimensions of Health Information Quality. Frontiers in Public Health, 2020, 8, 223.	2.7	0
18	Environmental risk factors and their footprints in vivo – A proposal for the classification of oxidative stress biomarkers. Redox Biology, 2020, 34, 101442.	9.0	43

#	Article	IF	CITATIONS
19	Vitamins D3 and D2 have marked but different global effects on gene expression in a rat oligodendrocyte precursor cell line. Molecular Medicine, 2020, 26, 32.	4.4	9
20	Boosting the Immune System, From Science to Myth: Analysis the Infosphere With Google. Frontiers in Medicine, 2019, 6, 165.	2.6	25
21	Inflammation-induced reactive nitrogen species cause proteasomal degradation of dimeric peroxiredoxin-1 in a mouse macrophage cell line. Free Radical Research, 2019, 53, 875-881.	3.3	3
22	Accuracy, completeness and accessibility of online information on fibromyalgia. Rheumatology International, 2019, 39, 735-742.	3.0	25
23	Precipitation of Soluble Uric Acid Is Necessary for In Vitro Activation of the NLRP3 Inflammasome in Primary Human Monocytes. Journal of Rheumatology, 2019, 46, 1141-1150.	2.0	19
24	Differential induction of nuclear factor-like 2 signature genes with toll-like receptor stimulation. Free Radical Biology and Medicine, 2019, 135, 245-250.	2.9	8
25	Secretion of IL-1Î ² From Monocytes in Gout Is Redox Independent. Frontiers in Immunology, 2019, 10, 70.	4.8	26
26	3D Bioprinting of Novel Biocompatible Scaffolds for Endothelial Cell Repair. Polymers, 2019, 11, 1924.	4.5	19
27	Association between inflammatory biomarkers and neointimal response following elective implantation of the ABSORB bioresorbable vascular scaffold. Coronary Artery Disease, 2019, 30, 183-187.	0.7	7
28	Cysteine/Glutathione Deficiency: A Significant and Treatable Corollary of Disease. , 2019, , 349-386.		6
29	Pharmacology, Formulations, and Adverse Effects. , 2019, , 387-394.		0
30	Online Information on Probiotics: Does It Match Scientific Evidence?. Frontiers in Medicine, 2019, 6, 296.	2.6	12
31	Theory of signs and statistical approach to big data in assessing the relevance of clinical biomarkers of inflammation and oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2473-2477.	7.1	14
32	Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacological Reviews, 2018, 70, 348-383.	16.0	441
33	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. Antioxidants and Redox Signaling, 2018, 28, 852-872.	5.4	62
34	Quality of online information on breast cancer treatment options. Breast, 2018, 37, 6-12.	2.2	64
35	Leukemia inhibitory factor inhibits erythropoietin-induced myelin gene expression in oligodendrocytes. Molecular Medicine, 2018, 24, 51.	4.4	6
36	What Is Health Information Quality? Ethical Dimension and Perception by Users. Frontiers in Medicine, 2018, 5, 260.	2.6	17

PIETRO GHEZZI

#	Article	IF	CITATIONS
37	Fake News or Weak Science? Visibility and Characterization of Antivaccine Webpages Returned by Google in Different Languages and Countries. Frontiers in Immunology, 2018, 9, 1215.	4.8	54
38	Breast cancer information on the internet: Type of websites, accuracy and readability of online resources. European Journal of Surgical Oncology, 2018, 44, S28.	1.0	2
39	The quality of online health information on breast augmentation. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2018, 71, e62-e63.	1.0	11
40	Assessment of HIF-1α expression and release following endothelial injury in-vitro and in-vivo. Molecular Medicine, 2018, 24, 22.	4.4	19
41	Redox Proteomics Applied to the Thiol Secretome. Antioxidants and Redox Signaling, 2017, 26, 299-312.	5.4	16
42	The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells. Molecular Cancer, 2017, 16, 3.	19.2	59
43	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biology, 2017, 13, 94-162.	9.0	242
44	Health information quality of websites on periodontology. Journal of Clinical Periodontology, 2017, 44, 308-314.	4.9	31
45	Using Machine Learning for Automatic Identification of Evidence-Based Health Information on the Web. , 2017, , .		7
46	The oxidative stress theory of disease: levels of evidence and epistemological aspects. British Journal of Pharmacology, 2017, 174, 1784-1796.	5.4	126
47	P30 THE ROLE OF NOVEL BIOMARKERS IN ARTERIAL STIFFNESS, AND IN PREDICTING FURTHER VASCULAR EVENTS AFTER TIA AND LACUNAR STROKE. Artery Research, 2017, 20, 101.	0.6	0
48	Breast cancer information on the internet: Type of websites, accuracy and readability of online resources. European Journal of Surgical Oncology, 2017, 43, 2226.	1.0	0
49	Online Information on Antioxidants: Information Quality Indicators, Commercial Interests, and Ranking by Google. Frontiers in Public Health, 2017, 5, 90.	2.7	26
50	Stem Cell Therapy on the Internet: Information Quality and Content Analysis of English Language Web Pages Returned by Google. Frontiers in ICT, 2017, 4, .	3.6	4
51	Glutathione Fine-Tunes the Innate Immune Response toward Antiviral Pathways in a Macrophage Cell Line Independently of Its Antioxidant Properties. Frontiers in Immunology, 2017, 8, 1239.	4.8	76
52	Erythropoietin Increases Myelination in Oligodendrocytes: Gene Expression Profiling Reveals Early Induction of Genes Involved in Lipid Transport and Metabolism. Frontiers in Immunology, 2017, 8, 1394.	4.8	14
53	Severity of Systemic Inflammatory Response Syndrome Affects the Blood Levels of Circulating Inflammatory-Relevant MicroRNAs. Frontiers in Immunology, 2017, 8, 1977.	4.8	44
54	Erythropoietin and a nonerythropoietic peptide analog promote aortic endothelial cell repair under hypoxic conditions: role of nitric oxide. Hypoxia (Auckland, N Z), 2016, Volume 4, 121-133.	1.9	17

#	Article	IF	CITATIONS
55	Response to I. Batinic-Haberle et al Antioxidants and Redox Signaling, 2016, 24, 525-526.	5.4	0
56	192â€Hypoxia Enhances the Reparative Effect of Tissue Protective Erythropoietin and Its Non-Erythropoietic Peptide Analogue in an Endothelial Cell Injury Model. Heart, 2016, 102, A130.2-A131.	2.9	0
57	ls erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way?. F1000Research, 2016, 5, 911.	1.6	5
58	Development of â€~Redox Arrays' for identifying novel glutathionylated proteins in the secretome. Scientific Reports, 2015, 5, 14630.	3.3	15
59	Bad News: Analysis of the Quality of Information on Influenza Prevention Returned by Google in English and Italian. Frontiers in Immunology, 2015, 6, 616.	4.8	26
60	Adding Dimensions to the Analysis of the Quality of Health Information of Websites Returned by Google: Cluster Analysis Identifies Patterns of Websites According to their Classification and the Type of Intervention Described. Frontiers in Public Health, 2015, 3, 204.	2.7	20
61	Low Oxygen Tension Primes Aortic Endothelial Cells to the Reparative Effect of Tissue-Protective Cytokines. Molecular Medicine, 2015, 21, 709-716.	4.4	6
62	Cysteine Oxidation Targets Peroxiredoxins 1 and 2 for Exosomal Release through a Novel Mechanism of Redox-Dependent Secretion. Molecular Medicine, 2015, 21, 98-108.	4.4	99
63	Is frailty in the elderly linked to inflammation?. Age and Ageing, 2015, 44, 913-914.	1.6	2
64	A Methodology to Analyze the Quality of Health Information on the Internet. The Diabetes Educator, 2015, 41, 95-105.	2.5	45
65	Clinical Relevance of Biomarkers of Oxidative Stress. Antioxidants and Redox Signaling, 2015, 23, 1144-1170.	5.4	604
66	Pharmacology and Clinical Drug Candidates in Redox Medicine. Antioxidants and Redox Signaling, 2015, 23, 1113-1129.	5.4	75
67	Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications. Antioxidants and Redox Signaling, 2015, 23, 1171-1185.	5.4	120
68	ID: 117. Cytokine, 2015, 76, 87-88.	3.2	0
69	Redox Proteomics of the Inflammatory Secretome Identifies a Common Set of Redoxins and Other Glutathionylated Proteins Released in Inflammation, Influenza Virus Infection and Oxidative Stress. PLoS ONE, 2015, 10, e0127086.	2.5	68
70	Definition of a Family of Tissue-Protective Cytokines Using Functional Cluster Analysis: A Proof-of-Concept Study. Frontiers in Immunology, 2014, 5, 115.	4.8	6
71	Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12157-12162.	7.1	293
72	Educating Medical Students to Evaluate the Quality of Health Information on the Web. Synthese Library, 2014, , 183-199.	0.2	5

#	Article	IF	CITATIONS
73	Protein glutathionylation in health and disease. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 3165-3172.	2.4	143
74	The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience, 2013, 233, 174-183.	2.3	26
75	Tissue-Protective Cytokines: Structure and Evolution. Methods in Molecular Biology, 2013, 982, 43-58.	0.9	14
76	Therapeutic Efficacy of Erythropoietin in Experimental Autoimmune Encephalomyelitis in Mice, a Model of Multiple Sclerosis. Methods in Molecular Biology, 2013, 982, 163-173.	0.9	15
77	Erythropoietin (EPO) Increases Myelin Gene Expression in CG4 Oligodendrocyte Cells through the Classical EPO Receptor. Molecular Medicine, 2013, 19, 223-229.	4.4	24
78	Quantification of Global Protein Disulfides and Thiol-Protein Mixed Disulfides to Study the Protein Dethiolation Mechanisms. American Journal of Analytical Chemistry, 2013, 04, 9-19.	0.9	2
79	Beneficial Effects of PKF275-055, a Novel, Selective, Orally Bioavailable, Long-Acting Dipeptidyl Peptidase IV Inhibitor in Streptozotocin-Induced Diabetic Peripheral Neuropathy. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 64-72.	2.5	41
80	Etanercept treatment in <scp>F</scp> anconi anaemia; combined <scp>US</scp> and <scp>I</scp> talian experience. British Journal of Haematology, 2012, 158, 809-811.	2.5	15
81	Erythropoietin Attenuates Neurological and Histological Consequences of Toxic Demyelination in Mice. Molecular Medicine, 2012, 18, 628-635.	4.4	38
82	Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9617-9622.	7.1	77
83	Erythropoietin induces myelin genes and the early growth factor 2 in oligodendrocytes through the classical erythropoietin receptor. FASEB Journal, 2012, 26, lb499.	0.5	0
84	A proteomic approach to identify proteins involved in Redox regulation of inflammation and immunity. FASEB Journal, 2012, 26, lb671.	0.5	0
85	Role of glutathione in immunity and inflammation in the lung. International Journal of General Medicine, 2011, 4, 105.	1.8	191
86	Thiol regulation of pro-inflammatory cytokines and innate immunity: protein S-thiolation as a novel molecular mechanism. Biochemical Society Transactions, 2011, 39, 1268-1272.	3.4	26
87	Neuropathologic and Biochemical Changes During Disease Progression in Liver X Receptor β ^{âr²/âr²} Mice, A Model of Adult Neuron Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 593-605.	1.7	38
88	The Neuroprotective Effect of Erythropoietin in Docetaxel-Induced Peripheral Neuropathy Causes No Reduction of Antitumor Activity in 13762 Adenocarcinoma-Bearing Rats. Neurotoxicity Research, 2010, 18, 151-160.	2.7	22
89	IL-1 family nomenclature. Nature Immunology, 2010, 11, 973-973.	14.5	294
90	Measurement of Mixed Disulfides Including Glutathionylated Proteins. Methods in Enzymology, 2010, 473, 149-159.	1.0	17

#	Article	IF	CITATIONS
91	Erythropoietin: not just about erythropoiesis. Lancet, The, 2010, 375, 2142.	13.7	48
92	Increased II-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis. European Journal of Inflammation, 2009, 7, 39-44.	0.5	12
93	Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor I®B. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14978-14983.	7.1	551
94	Etanercept as a salvage treatment for refractory aplastic anemia. Pediatric Blood and Cancer, 2009, 52, 522-525.	1.5	13
95	Detection of Protein Glutathionylation. Methods in Molecular Biology, 2009, 519, 397-415.	0.9	7
96	Erythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 410-415.	2.1	41
97	Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10925-10930.	7.1	280
98	TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6185-6190.	7.1	100
99	Endogenous Erythropoietin as Part of the Cytokine Network in the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Molecular Medicine, 2008, 14, 682-688.	4.4	13
100	Chemokine MIP-2/CXCL2, Acting on CXCR2, Induces Motor Neuron Death in Primary Cultures. NeuroImmunoModulation, 2007, 14, 310-316.	1.8	41
101	Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth. European Journal of Cancer, 2007, 43, 710-717.	2.8	58
102	Glutathionylation pathways in drug response. Current Opinion in Pharmacology, 2007, 7, 398-403.	3.5	50
103	The Interleukin-8 (IL-8/CXCL8) Receptor Inhibitor Reparixin Improves Neurological Deficits and Reduces Long-term Inflammation in Permanent and Transient Cerebral Ischemia in Rats. Molecular Medicine, 2007, 13, 125-133.	4.4	77
104	Activities of erythropoietin on tumors: An immunological perspective. European Journal of Immunology, 2007, 37, 1427-1430.	2.9	6
105	MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nature Medicine, 2007, 13, 587-596.	30.7	1,065
106	Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 552-563.	4.3	128
107	Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sciences, 2006, 79, 121-129.	4.3	96
108	Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo. Molecular Medicine, 2006, 12, 153-160.	4.4	82

#	Article	IF	CITATIONS
109	Redox regulation of cyclophilin A by glutathionylation. Proteomics, 2006, 6, 817-825.	2.2	43
110	Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 172, 27-37.	2.3	103
111	Thiol-Disulfide Oxidoreduction of Protein Cysteines: Old Methods Revisited for Proteomics. , 2006, , 101-122.		3
112	Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity. Clinical Cancer Research, 2006, 12, 2607-2612.	7.0	85
113	Regulation of redox-sensitive exofacial protein thiols in CHO cells. Biological Chemistry, 2006, 387, 1371-6.	2.5	28
114	Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5965-5970.	7.1	129
115	Role of Erythropoietin in Inflammatory Pathologies of the CNS. , 2006, , 191-209.		0
116	Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. European Cytokine Network, 2006, 17, 35-41.	2.0	28
117	Oxidoreduction of protein thiols in redox regulation. Biochemical Society Transactions, 2005, 33, 1378.	3.4	115
118	Tumor Necrosis Factor as a Pharmacological Target. Molecular Biotechnology, 2005, 31, 239-244.	2.4	41
119	ReviewRegulation of protein function by glutathionylation. Free Radical Research, 2005, 39, 573-580.	3.3	235
120	Inhibition of microglial inflammation by the MLK inhibitor CEPâ€1347. Journal of Neurochemistry, 2005, 92, 1439-1451.	3.9	65
121	Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. Journal of Neurochemistry, 2005, 93, 412-421.	3.9	143
122	Linking stress, oxidation and the chemokine system. European Journal of Immunology, 2005, 35, 3095-3098.	2.9	24
123	N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma. European Journal of Inflammation, 2005, 3, 17-22.	0.5	0
124	Gene expression profiling reveals a signaling role of glutathione in redox regulation. Proceedings of the United States of America, 2005, 102, 13998-14003.	7.1	164
125	Requirements for the Different Cysteines in the Chemotactic and Desensitizing Activity of Human Thioredoxin. Antioxidants and Redox Signaling, 2005, 7, 1189-1194.	5.4	25
126	A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2046-2051.	7.1	231

#	Article	IF	CITATIONS
127	Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine, 2005, 30, 125-131.	3.2	85
128	Thiol–Disulfide Balance: From the Concept of Oxidative Stress to that of Redox Regulation. Antioxidants and Redox Signaling, 2005, 7, 964-972.	5.4	231
129	Synergistic Combination of N-Acetylcysteine and Ribavirin to Protect from Lethal Influenza Viral Infection in a Mouse Model. International Journal of Immunopathology and Pharmacology, 2004, 17, 99-102.	2.1	62
130	Tumor Necrosis Factor as a Pharmacological Target. , 2004, 98, 001-008.		15
131	Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 823-828.	7.1	238
132	Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11791-11796.	7.1	310
133	Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14907-14912.	7.1	657
134	Redox proteomics: identification and functional role of glutathionylated proteins. Expert Review of Proteomics, 2004, 1, 365-376.	3.0	71
135	Animal Models of Endotoxic Shock. , 2004, 98, 199-206.		19
136	Glial activation and TNFR-I upregulation precedes motor dysfunction in the spinal cord of mnd mice. Cytokine, 2004, 25, 127-135.	3.2	20
137	Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. Journal of Molecular and Cellular Cardiology, 2004, 37, 959-968.	1.9	182
138	Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic. Science, 2004, 305, 239-242.	12.6	775
139	Granulocyte colony-stimulating factor decreases tumor necrosis factor production in whole blood: role of interleukin-10 and prostaglandin E(2). European Cytokine Network, 2004, 15, 323-6.	2.0	6
140	In vivo cardioprotection by N-acetylcysteine and isosorbide 5-mononitrate in a rat model of ischemia-reperfusion. Cardiovascular Drugs and Therapy, 2003, 17, 199-208.	2.6	15
141	Redox proteomics: Identification of oxidatively modified proteins. Proteomics, 2003, 3, 1145-1153.	2.2	246
142	Identification of proteins undergoing glutathionylation in oxidatively stressed hepatocytes and hepatoma cells. Proteomics, 2003, 3, 1154-1161.	2.2	165
143	Inhibition of Nuclear Factor-κB by a Nitro-Derivative of Flurbiprofen: A Possible Mechanism for Antiinflammatory and Antiproliferative Effect. Antioxidants and Redox Signaling, 2003, 5, 229-235.	5.4	14
144	Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis. Journal of Experimental Medicine, 2003, 198, 971-975.	8.5	481

PIETRO GHEZZI

#	Article	IF	CITATIONS
145	Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4802-4806.	7.1	556
146	Redox regulation of surface protein thiols: Identification of integrin Â-4 as a molecular target by using redox proteomics. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14737-14741.	7.1	124
147	Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> . Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6741-6746.	7.1	416
148	Carbocysteine lysine salt monohydrate (SCMC-LYS) is a selective scavenger of reactive oxygen intermediates (ROIs). European Cytokine Network, 2003, 14, 20-6.	2.0	35
149	Glutathionylation of human thioredoxin: A possible crosstalk between the glutathione and thioredoxin systems. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9745-9749.	7.1	325
150	Glutathione Protects Mice from Lethal Sepsis by Limiting Inflammation and Potentiating Host Defense. Journal of Infectious Diseases, 2002, 185, 1115-1120.	4.0	77
151	Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3505-3510.	7.1	536
152	Neuroprotective properties of epoetin alfa. Nephrology Dialysis Transplantation, 2002, 17, 8-12.	0.7	66
153	HMGB-1, A DNA-BINDING PROTEIN WITH CYTOKINE ACTIVITY, INDUCES BRAIN TNF AND IL-6 PRODUCTION, AND MEDIATES ANOREXIA AND TASTE AVERSION. Cytokine, 2002, 18, 231-236.	3.2	143
154	THIOL ANTIOXIDANTS INHIBIT THE FORMATION OF THE INTERLEUKIN-12 HETERODIMER: A NOVEL MECHANISM FOR THE INHIBITION OF IL-12 PRODUCTION. Cytokine, 2002, 17, 285-293.	3.2	17
155	Preventive administration of Mycobacterium tuberculosis 10-kDa heat shock protein (hsp10) suppresses adjuvant arthritis in Lewis rats. International Immunopharmacology, 2002, 2, 463-474.	3.8	25
156	Protein glutathionylation: coupling and uncoupling of glutathione to protein thiol groups in lymphocytes under oxidative stress and HIV infection. Molecular Immunology, 2002, 38, 773-780.	2.2	90
157	Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Research, 2002, 952, 128-134.	2.2	326
158	Thioredoxin specifically cross-desensitizes monocytes to MCP-1. European Cytokine Network, 2002, 13, 261-7.	2.0	12
159	ROLE OF CYTOKINES IN CANCER CACHEXIA IN A MURINE MODEL OF INTRACEREBRAL INJECTION OF HUMAN TUMOURS. Cytokine, 2001, 15, 27-38.	3.2	32
160	Tumor Necrosis Factor and Motoneuronal Degeneration: An Open Problem. NeuroImmunoModulation, 2001, 9, 178-182.	1.8	57
161	Cardiac protection by pharmacological modulation of inflammation. Expert Opinion on Investigational Drugs, 2001, 10, 1913-1924.	4.1	3
162	Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2688-2693.	7.1	131

#	Article	IF	CITATIONS
163	Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proceedings of the United States of America, 2001, 98, 4044-4049.	7.1	928
164	Effects of epoetin alfa on the central nervous system. Seminars in Oncology, 2001, 28, 66-70.	2.2	45
165	Proteins of rat serum V: Adjuvant arthritis and its modulation by nonsteroidal anti-inflammatory drugs. Electrophoresis, 2000, 21, 2170-2180.	2.4	32
166	Inducible expression of the long pentraxin PTX3 in the central nervous system. Journal of Neuroimmunology, 2000, 106, 87-94.	2.3	73
167	Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. Journal of Neuroimmunology, 2000, 109, 105-111.	2.3	48
168	Increased tumor necrosis factor and interleukin-6 production in the central nervous system of interleukin-10-deficient mice. Brain Research, 2000, 869, 241-243.	2.2	28
169	Decrease in Brain Cytochrome P450 Enzyme Activities during Infection and Inflammation of the Central Nervous System. NeuroImmunoModulation, 2000, 8, 142-147.	1.8	22
170	Redox regulation of chemokine receptor expression. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2761-2766.	7.1	110
171	LPS INDUCES IL-6 IN THE BRAIN AND IN SERUM LARGELY THROUGH TNF PRODUCTION. Cytokine, 2000, 12, 1205-1210.	3.2	49
172	Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10526-10531.	7.1	1,308
173	PTX3, A Prototypical Long Pentraxin, Is an Early Indicator of Acute Myocardial Infarction in Humans. Circulation, 2000, 102, 636-641.	1.6	384
174	Peripheral Effects of Centrally Administered Interleukin-1β in Mice in Relation to Its Clearance from the Brain into the Blood and Tissue Distribution. NeuroImmunoModulation, 1999, 6, 300-304.	1.8	18
175	Inhibition of Systemic Inflammation by Central Action of the Neuropeptide α-Melanocyte- Stimulating Hormone. NeuroImmunoModulation, 1999, 6, 187-192.	1.8	44
176	Thioredoxin, a Redox Enzyme Released in Infection and Inflammation, Is a Unique Chemoattractant for Neutrophils, Monocytes, and T Cells. Journal of Experimental Medicine, 1999, 189, 1783-1789.	8.5	303
177	Regulation of Inhibitory Pathways of the Interleukin-1 System. Annals of the New York Academy of Sciences, 1998, 840, 338-351.	3.8	52
178	Mycobacterial Cpn10 promotes recognition of the mammalian homologue by a mycobacterium-specific antiserum. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1403, 151-157.	4.1	4
179	MK 801 and dexamethasone reduce both tumor necrosis factor levels and infarct volume after focal cerebral ischemia in the rat brain. Neuroscience Letters, 1998, 246, 41-44.	2.1	68
180	WITHIN-PATIENT VARIABILITY OF HORMONE AND CYTOKINE CONCENTRATIONS IN HEART FAILURE. Pharmacological Research, 1998, 37, 213-217.	7.1	25

#	Article	IF	CITATIONS
181	Intracerebroventricular Injection of Anti-Fas Activates the Hypothalamus-Pituitary-Adrenal Axis and Induces Peripheral Interleukin-6 and Serum Amyloid A in Mice. American Journal of Pathology, 1998, 153, 1377-1381.	3.8	5
182	Mechanism of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro. European Journal of Pharmacology, 1998, 343, 249-255.	3.5	48
183	Granulocyte Colony-Stimulating Factor and Antibiotics in the Prophylaxis of a Murine Model of Polymicrobial Peritonitis and Sepsis. Journal of Infectious Diseases, 1998, 178, 471-477.	4.0	41
184	Interleukin 1. , 1998, , 1-18.		6
185	Leptin causes body weight loss in the absence of in vivo activities typical of cytokines of the IL-6 family. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R913-R919.	1.8	13
186	Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E757-E762.	3.5	33
187	Nonsteroidal Antiâ€Inflammatory Drugs Increase Tumor Necrosis Factor Production in the Periphery but Not in the Central Nervous System in Mice and Rats. Journal of Neurochemistry, 1998, 71, 2063-2070.	3.9	30
188	Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor. Mediators of Inflammation, 1997, 6, 32-38.	3.0	70
189	Centrally Mediated Inhibition of Local Inflammation by Ciliary Neurotrophic Factor. NeuroImmunoModulation, 1997, 4, 271-276.	1.8	15
190	TUMOR NECROSIS FACTOR IS A BRAIN DAMAGING CYTOKINE IN CEREBRAL ISCHEMIA. Shock, 1997, 8, 141-348.	2.1	121
191	Time course of circulating acute phase proteins and cytokines in septic patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 33-39.	3.0	4
192	Systemic interleukin 10 administration inhibits brain tumor necrosis factor production in mice. European Journal of Pharmacology, 1997, 336, 197-202.	3.5	24
193	DIFFERENTIAL EFFECTS OF IL-6 ON SYSTEMIC AND CENTRAL PRODUCTION OF TNF: A STUDY WITH IL-6-DEFICIENT MICE. Cytokine, 1997, 9, 300-306.	3.2	48
194	Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment. Immunity, 1997, 6, 315-325.	14.3	1,022
195	Hyperresponsive febrile reactions to interleukin (IL) 1Â and IL-1Â, and altered brain cytokine mRNA and serum cytokine levels, in IL-1Â-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 2681-2686.	7.1	91
196	Protective Effect of a Single Interleukin-12 (IL-12) Predose Against the Toxicity of Subsequent Chronic IL-12 in Mice: Role of Cytokines and Glucocorticoids. Blood, 1997, 90, 4473-4479.	1.4	37
197	Protective Effect of a Single Interleukin-12 (IL-12) Predose Against the Toxicity of Subsequent Chronic IL-12 in Mice: Role of Cytokines and Glucocorticoids. Blood, 1997, 90, 4473-4479.	1.4	2
198	A glucocorticoid receptor-independent mechanism for neurosteroid inhibition of tumor necrosis factor production. European Journal of Pharmacology, 1996, 299, 179-186.	3.5	34

PIETRO GHEZZI

#	Article	IF	CITATIONS
199	Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice. European Journal of Pharmacology, 1996, 317, 369-376.	3.5	16
200	DHEAS Inhibits TNF Production in Monocytes, Astrocytes and Microglial Cells. NeuroImmunoModulation, 1996, 3, 285-288.	1.8	40
201	Mycobacterium tuberculosis heart shock protein 10 increases both proliferation and death in mouse P19 teratocarcinoma cells. In Vitro Cellular and Developmental Biology - Animal, 1996, 32, 446-450.	1.5	14
202	Overexpression of interleukin-6 in the central nervous system of transgenic mice increases central but not systemic proinflammatory cytokine production. Brain Research, 1996, 740, 239-244.	2.2	42
203	Regional Production of Nitric Oxide after a Peripheral or Central Low Dose of LPS in Mice. NeuroImmunoModulation, 1996, 3, 364-370.	1.8	6
204	Bradykinin B2 Receptor Involvement in Rabbit and Murine Models of Septic Shock. Journal of Cardiovascular Pharmacology, 1996, 27, 500-507.	1.9	14
205	Interleukin-10 Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor and Interleukin-1β Production in the Brain without Affecting the Activation of the Hypothalamus-Pituitary-Adrenal Axis. NeuroImmunoModulation, 1995, 2, 149-154.	1.8	53
206	Proinflammatory Cytokines as Pathogenetic Mediators in the Central Nervous System: Brain-Periphery Connections. NeuroImmunoModulation, 1995, 2, 2-15.	1.8	38
207	The upregulating effect of dexamethasone on tumor necrosis factor production is mediated by a nitric oxide-producing cytochrome P450. Cellular Immunology, 1995, 160, 305-308.	3.0	14
208	Ciliary Neurotrophic Factor Inhibits Brain and Peripheral Tumor Necrosis Factor Production and, When Coadministered with Its Soluble Receptor, Protects Mice From Lipopolysaccharide Toxicity. Molecular Medicine, 1995, 1, 568-575.	4.4	25
209	Second International Cytokine Conference, Banff, Alberta October 1–5, 1994. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 66-68.	3.0	0
210	Role of IL-1β and corticosteroids in the regulation of the C/EBP-α, β and δ genes in vivo. Cytokine, 1995, 7, 753-758.	3.2	25
211	Ciliary Neurotrophic Factor (CNTF) Induces Serum Amyloid A, Hypoglycaemia and Anorexia, and Potentiates IL-1 Induced Corticosterone and IL-6 Production in Mice. Cytokine, 1995, 7, 150-156.	3.2	40
212	Effect of on sepsis in mice. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 292, 341-344.	0.8	19
213	Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 292, 257-263.	0.8	12
214	Cytokines in Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology, 1994, 23, 1-6.	1.9	90
215	Cytokines in Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology, 1994, 23, 1.	1.9	129
216	Mast cells do not contribute to the rapid appearance of the TNF in the serum of LPS-treated mice: A study with mast cell-deficient mice. International Journal of Immunopharmacology, 1993, 15, 551-555.	1.1	6

#	Article	IF	CITATIONS
217	Inhibitors of Cytochrome P450 Suppress Tumor Necrosis Factor Production. Cellular Immunology, 1993, 150, 417-424.	3.0	16
218	The pneumotoxicant paraquat induces IL-8 mRNA in human mononuclear cells and pulmonary epithelial cells. Cytokine, 1993, 5, 525-530.	3.2	24
219	Reactive Oxygen Intermediates in Tumor Necrosis Factor Production and Endotoxic Shock. , 1993, , 113-119.		0
220	Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases. Mediators of Inflammation, 1993, 2, 263-270.	3.0	67
221	Evidence for a different sensitivity to various central effects of interleukin-1 β in mice. Brain Research Bulletin, 1992, 28, 161-165.	3.0	25
222	Diffferential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. International Journal of Immunopharmacology, 1992, 14, 1045-1050.	1.1	51
223	N-Acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cellular Immunology, 1992, 140, 390-399.	3.0	233
224	Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. Cytokine, 1991, 3, 189-194.	3.2	243
225	Interleukin 6 activity in infants and children with bacterial meningitis. Pediatric Infectious Disease Journal, 1991, 10, 117-121.	2.0	64
226	Chlorpromazine protection against interleukin-1 and tumor necrosis factor-mediated activities in vivo. International Journal of Immunopharmacology, 1991, 13, 1085-1090.	1.1	11
227	Defective Tolerance to the Toxic and Metabolic Effects of Interleukin 1. Endocrinology, 1991, 128, 1668-1672.	2.8	25
228	Differential activity of interleukin 1α and interleukin 1β in the stimulation of the immune responsein vivo. European Journal of Immunology, 1990, 20, 317-321.	2.9	57
229	Purification and characterization of mouse liver xanthine oxidase. Archives of Biochemistry and Biophysics, 1990, 279, 237-241.	3.0	28
230	Dexamethasone Modulation of In Vivo Effects of Endotoxin, Tumor Necrosis Factor, and Interleukin-1 on Liver Cytochrome P-450, Plasma Fibrinogen, and Serum Iron. Journal of Leukocyte Biology, 1989, 46, 254-262.	3.3	69
231	Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: Role of antioxidant enzymes and effect of cyclooxygenase inhibitors. Biotherapy (Dordrecht, Netherlands), 1989, 1, 361-367.	0.7	42
232	Protective effect of chlorpromazine against the lethality of interleukin 1 in adrenalectomized or actinomicin D-sensitized mice. Biochemical and Biophysical Research Communications, 1989, 165, 942-946.	2.1	26
233	Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin 1 and tumor necrosis factor: A comparison with lymphotoxin and interferon. International Journal of Immunopharmacology, 1988, 10, 525-530.	1.1	39
234	Induction of indoleamine dioxygenase by interferon in mice: A study with different recombinant interferons and various cytokines. Biochemical and Biophysical Research Communications, 1988, 152, 237-242.	2.1	46

#	Article	IF	CITATIONS
235	Depression of liver drug metabolism in sarcoma-bearing mice. Evidence for a circulating factor and dissociation from lipolytic activity. European Journal of Cancer & Clinical Oncology, 1988, 24, 1845-1849.	0.7	5
236	Defective Production of Reactive Oxygen Intermediates by Tumor-Associated Macrophages Exposed to Phorbol Ester. Journal of Leukocyte Biology, 1987, 42, 84-90.	3.3	9
237	Time-Dependent Differential Effects of Natural and Recombinant Murine Interferon-Gamma on Ornithine Decarboxylase Activity of Tumor Cells1. Journal of Biochemistry, 1987, 101, 927-932.	1.7	0
238	Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochemical and Biophysical Research Communications, 1986, 136, 316-321.	2.1	114
239	Role of reactive oxygen intermediates in the hepatotoxicity of endotoxin. Immunopharmacology, 1986, 12, 241-244.	2.0	22
240	Induction of Xanthine Oxidase and Heme Oxygenase and Depression of Liver Drug Metabolism by Interferon: A Study with Different Recombinant Interferons. Journal of Interferon Research, 1986, 6, 251-256.	1.2	34
241	Dissociation between induction of ornithine decarboxylase and oxidative burst by phorbol esters in a macrophage cell line. Carcinogenesis, 1986, 7, 1297-1299.	2.8	1
242	Rapid killing of actinomycin D-treated tumor cells-cytotoxicity of cell-free monocyte supernatants. Immunology Letters, 1985, 11, 351-355.	2.5	3
243	Platelet derived growth factor induces ornithine decarboxylase activity in nih 3T3 cells. Biochemical and Biophysical Research Communications, 1985, 127, 843-848.	2.1	11
244	Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers. Biochemical and Biophysical Research Communications, 1984, 119, 144-149.	2.1	83
245	Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: Evidence for a role in the regulation of the macrophage content of neoplastic tissues. International Journal of Cancer, 1983, 31, 55-63.	5.1	55
246	Plasma pyroglutamic acid levels after oral administration of monosodium glutamate to human volunteers. Toxicology Letters, 1983, 15, 123-129.	0.8	10
247	N-Acetyl-β-d-glucosaminidase (NAG) and NAG isoenzymes in children with upper and lower urinary tract infections. Clinica Chimica Acta, 1983, 130, 297-304.	1.1	28
248	Evidence for covalent binding of adriamycin to rat liver microsomal proteins. Biochemical Pharmacology, 1981, 30, 175-177.	4.4	33
249	Regulation of Protein Function by Glutathionylation. , 0, , 189-209.		1
250	Online Information of Vaccines: Information Quality, Not Only Privacy, Is an Ethical Responsibility of Search Engines. SSRN Electronic Journal, 0, , .	0.4	0
251	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. SSRN Electronic Journal, 0, , .	0.4	0